{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:23:27Z","timestamp":1793391807683,"version":"4.5.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T00:00:00Z","timestamp":1620172800000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006662","name":"NIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clinician Scientist and Senior Clinical Research Fellow"},{"name":"NIHR Clinician Scientist"},{"name":"Oxford Biomedical Research Centre"},{"DOI":"10.13039\/501100003921","name":"Department of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>As our understanding of the pathogenesis of SpA improves, focus has turned to the role janus kinase (JAK)-mediated signal transduction and inhibiting its actions as a therapeutic mechanism. Small molecule inhibitors of JAK exist, with variable selectivity for the different JAK isoforms. Less selective JAK inhibitors have variable efficacy and safety profiles, prompting the investigation of selective JAK1 inhibition. In this review, we summarize the current phase 2 and 3 clinical trial data, evaluating the use of JAK1 selective inhibitors in the treatment of SpA, particularly AS and PsA. Selective JAK1 inhibition offers a promising therapeutic approach, however further longer-term trials are needed to fully establish their efficacy and safety at higher doses, and their use in the greater continuum of SpA.<\/jats:p>","DOI":"10.1093\/rheumatology\/keaa815","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T20:34:33Z","timestamp":1605904473000},"page":"ii39-ii44","source":"Crossref","is-referenced-by-count":9,"title":["JAK1 selective inhibitors for the treatment of spondyloarthropathies"],"prefix":"10.1093","volume":"60","author":[{"given":"Jonathan P E","family":"White","sequence":"first","affiliation":[{"name":"Rheumatology SHO, Nuffield Orthopaedic Centre, Oxford University Hospitals NHS Trust"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4756-663X","authenticated-orcid":false,"given":"Laura C","family":"Coates","sequence":"additional","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford , Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,5,5]]},"reference":[{"key":"2022061310423270500_keaa815-B1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/1759720X18773726","article-title":"Ankylosing spondylitis and axial spondyloarthritis: recent insights and impact of new classification criteria","volume":"10","author":"Proft","year":"2018","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2022061310423270500_keaa815-B2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/rheumatology\/key070","article-title":"The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis","volume":"58","author":"Veal","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2022061310423270500_keaa815-B3","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"2022061310423270500_keaa815-B4","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/rheumatology\/key339","article-title":"Clinical significance of Janus Kinase inhibitor selectivity","volume":"58","author":"Choy","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2022061310423270500_keaa815-B5","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.berh.2019.01.014","article-title":"Emerging treatment options for spondyloarthritis","volume":"32","author":"Torgutalp","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2022061310423270500_keaa815-B6","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1136\/annrheumdis-2013-204934","article-title":"Is there a need for new agents with novel mechanisms of action in psoriatic arthritis?","volume":"73","author":"Orr","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2022061310423270500_keaa815-B7","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022061310423270500_keaa815-B8","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/annrheumdis-2020-217163","article-title":"Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis","volume":"79","author":"Kerschbaumer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022061310423270500_keaa815-B9","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med"},{"key":"2022061310423270500_keaa815-B10","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N Engl J Med"},{"key":"2022061310423270500_keaa815-B11","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo- controlled, dose-ranging study","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022061310423270500_keaa815-B12","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1093\/rheumatology\/key104","article-title":"Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients","volume":"57","author":"Maksymowych","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2022061310423270500_keaa815-B13","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/S0140-6736(18)32463-2","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"key":"2022061310423270500_keaa815-B14","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"van der Heijde","year":"2019","journal-title":"Lancet"},{"key":"2022061310423270500_keaa815-B15","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/S0140-6736(18)32483-8","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Mease","year":"2018","journal-title":"Lancet"},{"key":"2022061310423270500_keaa815-B16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/annrheumdis-2020-eular.6727","article-title":"Efficacy and safety of upadacitinib versus placebo and adalimumab in patients with active psoriatic arthritis and inadequate response to non-biologic disease-modifying ant-rheumatic drugs (SELECT-PsA-1): a double-blind, randomized controlled phase 3 trial","volume":"79","author":"Mcinnes","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022061310423270500_keaa815-B17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/annrheumdis-2020-eular.1229","article-title":"Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and inadequate response to biologic disease-modifying ant-rheumatic drugs (SELECT-PsA-2): a double-blind, randomized controlled phase 3 trial","volume":"79","author":"Genovese","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022061310423270500_keaa815-B18","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/annrheumdis-2016-210105","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)","volume":"76","author":"Kavanaugh","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022061310423270500_keaa815-B19","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/annrheumdis-2016-210104","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)","volume":"76","author":"Westhovens","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022061310423270500_keaa815-B20","year":"2018"},{"key":"2022061310423270500_keaa815-B21","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1136\/annrheumdis-2019-216761","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/Supplement_2\/ii39\/44040711\/keaa815.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/Supplement_2\/ii39\/44040711\/keaa815.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T10:43:14Z","timestamp":1655116994000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/Supplement_2\/ii39\/6265519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,1]]},"references-count":21,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2021,5,5]]},"published-print":{"date-parts":[[2021,5,5]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa815","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5,1]]},"published":{"date-parts":[[2021,5,1]]}}}